Dr. Muley highlights patient-reported experience from MINT: the once-every-six-month maintenance regimen (after initial ...
Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four ...
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T ...
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
A peer review how-to: accepting or declining review invitations, mentored reviews, reviewer checklists, and writing constructive comments authors can use.
Dr. Muley explains the rationale for examining disease duration: concern that longer disease may reduce reversibility due to ...
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic ...
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results